Clinical Trial Results:
Relative bioavailability study to investigate the pharmacokinetics, safety and tolerability of a single oral dose of finerenone 20 mg as suspension (pediatric formulation), intact tablet and crushed tablet (adult formulation) in the fasting condition, and to investigate the effect of a high fat, high calorie meal on the suspension in healthy male subjects in a randomized, open-label, four-fold crossover design
Summary
|
|
EudraCT number |
2016-002813-24 |
Trial protocol |
DE |
Global end of trial date |
01 Mar 2017
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
25 Jan 2018
|
First version publication date |
25 Jan 2018
|
Other versions |
Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
|
|||
Trial identification
|
|||
Sponsor protocol code |
BAY94-8862/16538
|
||
Additional study identifiers
|
|||
ISRCTN number |
- | ||
US NCT number |
NCT02957396 | ||
WHO universal trial number (UTN) |
- | ||
Sponsors
|
|||
Sponsor organisation name |
Bayer AG
|
||
Sponsor organisation address |
Kaiser-Wilhelm-Allee, D-51368 Leverkusen, Germany,
|
||
Public contact |
Therapeutic Area Head, Bayer AG, clinical-trials-contact@bayer.com
|
||
Scientific contact |
Therapeutic Area Head, Bayer AG, clinical-trials-contact@bayer.com
|
||
Paediatric regulatory details
|
|||
Is trial part of an agreed paediatric investigation plan (PIP) |
Yes
|
||
EMA paediatric investigation plan number(s) |
EMEA-001623-PIP01-14 | ||
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Results analysis stage
|
|||
Analysis stage |
Final
|
||
Date of interim/final analysis |
01 Mar 2017
|
||
Is this the analysis of the primary completion data? |
No
|
||
Global end of trial reached? |
Yes
|
||
Global end of trial date |
01 Mar 2017
|
||
Was the trial ended prematurely? |
No
|
||
General information about the trial
|
|||
Main objective of the trial |
The primary objectives of this study were to
1. investigate the relative bioavailability of a single oral dose of 20 milligram (mg) finerenone suspension and 20 mg crushed and re-suspended tablet in comparison to 20 mg finerenone tablet in the fasting condition;
2. investigate the effect of a high fat, high calorie meal on the pharmacokinetics (PK) of a single oral dose of 20 mg finerenone suspension;
3. investigate whether 20 mg finerenone suspension and 20 mg crushed and re-suspended tablet are palatable and swallowable by using a questionnaire regarding overall impression, appearance, smell, taste, texture, and swallowability.
|
||
Protection of trial subjects |
The conduct of this clinical study met all local legal and regulatory requirements. The study was conducted in accordance with the ethical principles that have their origin in the Declaration of Helsinki and the International Conference on Harmonization guideline E6: Good Clinical Practice. Before entering the study, the informed consent form was read by and explained to all subjects. Participating subjects signed informed consent form and could withdraw from the study at any time without any disadvantage and without having to provide a reason for this decision. Only investigators qualified by training and experience were selected as appropriate experts to investigate the study drug.
|
||
Background therapy |
- | ||
Evidence for comparator |
- | ||
Actual start date of recruitment |
17 Nov 2016
|
||
Long term follow-up planned |
No
|
||
Independent data monitoring committee (IDMC) involvement? |
No
|
||
Population of trial subjects
|
|||
Number of subjects enrolled per country |
|||
Country: Number of subjects enrolled |
Germany: 16
|
||
Worldwide total number of subjects |
16
|
||
EEA total number of subjects |
16
|
||
Number of subjects enrolled per age group |
|||
In utero |
0
|
||
Preterm newborn - gestational age < 37 wk |
0
|
||
Newborns (0-27 days) |
0
|
||
Infants and toddlers (28 days-23 months) |
0
|
||
Children (2-11 years) |
0
|
||
Adolescents (12-17 years) |
0
|
||
Adults (18-64 years) |
16
|
||
From 65 to 84 years |
0
|
||
85 years and over |
0
|
|
||||||||||||||||
Recruitment
|
||||||||||||||||
Recruitment details |
Study was conducted at one study center in Germany, between 17 November 2016 (first subject first visit) and 13 January 2017 (last subject last visit). | |||||||||||||||
Pre-assignment
|
||||||||||||||||
Screening details |
Overall, 36 subjects were enrolled, of them 20 subjects were not included into the study. A total of 16 subjects were randomized and received all the treatments in a four-fold cross-over fashion (A-D-C-B, B-C-D-A, C-A-B-D, or D-B-A-C) and completed the study. | |||||||||||||||
Period 1
|
||||||||||||||||
Period 1 title |
Overall Trial (overall period)
|
|||||||||||||||
Is this the baseline period? |
Yes | |||||||||||||||
Allocation method |
Not applicable
|
|||||||||||||||
Blinding used |
Not blinded | |||||||||||||||
Arms
|
||||||||||||||||
Are arms mutually exclusive |
Yes
|
|||||||||||||||
Arm title
|
Treatment A-D-C-B | |||||||||||||||
Arm description |
Subjects who followed treatment sequence A-D-C-B in fasted and fed state were reported. Subjects received a single oral dose of 20 mg finerenone (BAY94-8862) intact film-coated tablet in fasted state (Treatment A) in the first intervention period; followed by a single oral dose of 20 mg finerenone suspension (10 milliliter [mL]) after a standardized high-fat, high-calorie American breakfast in fed state (Treatment D) in the second intervention period; followed by a single oral dose of 20 mg finerenone suspension (10 mL) in fasted state (Treatment C) in the third intervention period; followed by a single oral dose of 20 mg finerenone crushed and re-suspended film-coated tablet in fasted state (Treatment B) in the fourth intervention period. A wash-out period of at least 72 hours was maintained between finerenone administrations. | |||||||||||||||
Arm type |
Experimental | |||||||||||||||
Investigational medicinal product name |
Finerenone
|
|||||||||||||||
Investigational medicinal product code |
BAY94-8862
|
|||||||||||||||
Other name |
||||||||||||||||
Pharmaceutical forms |
Film-coated tablet, Oral suspension
|
|||||||||||||||
Routes of administration |
Oral use
|
|||||||||||||||
Dosage and administration details |
Treatment A: Subjects received a single oral dose of 20 mg finerenone intact film-coated tablet in fasted state.
Treatment D: Subjects received a single oral dose of 20 mg finerenone suspension (10 mL) after a standardized high-fat, high-calorie American breakfast in fed state.
Treatment C: Subjects received a single oral dose of 20 mg finerenone suspension (10 mL) in fasted state.
Treatment B: Subjects received a single oral dose of 20 mg finerenone crushed and re-suspended film-coated tablet in fasted state.
|
|||||||||||||||
Arm title
|
Treatment B-C-D-A | |||||||||||||||
Arm description |
Subjects who followed treatment sequence B-C-D-A in fasted and fed state were reported. Subjects received a single oral dose of 20 mg finerenone crushed and re-suspended film-coated tablet in fasted state (Treatment B) in the first intervention period; followed by a single oral dose of 20 mg finerenone suspension (10 mL) in fasted state (Treatment C) in the second intervention period; followed by a single oral dose of 20 mg finerenone suspension (10 mL) after a standardized high-fat, high-calorie American breakfast in fed state (Treatment D) in the third intervention period; followed by a single oral dose of 20 mg finerenone intact film-coated tablet in fasted state (Treatment A) in the fourth intervention period. A wash-out period of at least 72 hours was maintained between finerenone administrations. | |||||||||||||||
Arm type |
Experimental | |||||||||||||||
Investigational medicinal product name |
Finerenone
|
|||||||||||||||
Investigational medicinal product code |
BAY94-8862
|
|||||||||||||||
Other name |
||||||||||||||||
Pharmaceutical forms |
Film-coated tablet, Oral suspension
|
|||||||||||||||
Routes of administration |
Oral use
|
|||||||||||||||
Dosage and administration details |
Treatment B: Subjects received a single oral dose of 20 mg finerenone crushed and re-suspended film-coated tablet in fasted state.
Treatment C: Subjects received a single oral dose of 20 mg finerenone suspension (10 mL) in fasted state.
Treatment D: Subjects received a single oral dose of 20 mg finerenone suspension (10 mL) after a standardized high-fat, high-calorie American breakfast in fed state.
Treatment A: Subjects received a single oral dose of 20 mg finerenone intact film-coated tablet in fasted state.
|
|||||||||||||||
Arm title
|
Treatment C-A-B-D | |||||||||||||||
Arm description |
Subjects who followed treatment sequence C-A-B-D in fasted and fed state were reported. Subjects received a single oral dose of 20 mg finerenone suspension (10 mL) in fasted state (Treatment C) in the first intervention period; followed by a single oral dose of 20 mg finerenone intact film-coated tablet in fasted state (Treatment A) in the second intervention period; followed by a single oral dose of 20 mg finerenone crushed and re-suspended film-coated tablet in fasted state (Treatment B) in the third intervention period; followed by a single oral dose of 20 mg finerenone suspension (10 mL) after a standardized high-fat, high-calorie American breakfast in fed state (Treatment D) in the fourth intervention period. A wash-out period of at least 72 hours was maintained between finerenone administrations. | |||||||||||||||
Arm type |
Experimental | |||||||||||||||
Investigational medicinal product name |
Finerenone
|
|||||||||||||||
Investigational medicinal product code |
BAY94-8862
|
|||||||||||||||
Other name |
||||||||||||||||
Pharmaceutical forms |
Film-coated tablet, Oral suspension
|
|||||||||||||||
Routes of administration |
Oral use
|
|||||||||||||||
Dosage and administration details |
Treatment C: Subjects received a single oral dose of 20 mg finerenone suspension (10 mL) in fasted state.
Treatment A: Subjects received a single oral dose of 20 mg finerenone intact film-coated tablet in fasted state.
Treatment B: Subjects received a single oral dose of 20 mg finerenone crushed and re-suspended film-coated tablet in fasted state.
Treatment D: Subjects received a single oral dose of 20 mg finerenone suspension (10 mL) after a standardized high-fat, high-calorie American breakfast in fed state.
|
|||||||||||||||
Arm title
|
Treatment D-B-A-C | |||||||||||||||
Arm description |
Subjects who followed treatment sequence D-B-A-C in fed and fasted state were reported. Subjects received a single oral dose of 20 mg finerenone suspension (10 mL) after a standardized high-fat, high-calorie American breakfast in fed state (Treatment D) in the first intervention period; followed by a single oral dose of 20 mg finerenone crushed and re-suspended film-coated tablet in fasted state (Treatment B) in the second intervention period; followed by a single oral dose of 20 mg finerenone intact film-coated tablet in fasted state (Treatment A) in the third intervention period; followed by a single oral dose of 20 mg finerenone suspension (10 mL) in fasted state (Treatment C) in the fourth intervention period. A wash-out period of at least 72 hours was maintained between finerenone administrations. | |||||||||||||||
Arm type |
Experimental | |||||||||||||||
Investigational medicinal product name |
Finerenone
|
|||||||||||||||
Investigational medicinal product code |
BAY94-8862
|
|||||||||||||||
Other name |
||||||||||||||||
Pharmaceutical forms |
Film-coated tablet, Oral suspension
|
|||||||||||||||
Routes of administration |
Oral use
|
|||||||||||||||
Dosage and administration details |
Treatment D: Subjects received a single oral dose of 20 mg finerenone suspension (10 mL) after a standardized high-fat, high-calorie American breakfast in fed state.
Treatment B: Subjects received a single oral dose of 20 mg finerenone crushed and re-suspended film-coated tablet in fasted state.
Treatment A: Subjects received a single oral dose of 20 mg finerenone intact film-coated tablet in fasted state.
Treatment C: Subjects received a single oral dose of 20 mg finerenone suspension (10 mL) in fasted state.
|
|||||||||||||||
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Baseline characteristics reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Treatment A-D-C-B
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Subjects who followed treatment sequence A-D-C-B in fasted and fed state were reported. Subjects received a single oral dose of 20 mg finerenone (BAY94-8862) intact film-coated tablet in fasted state (Treatment A) in the first intervention period; followed by a single oral dose of 20 mg finerenone suspension (10 milliliter [mL]) after a standardized high-fat, high-calorie American breakfast in fed state (Treatment D) in the second intervention period; followed by a single oral dose of 20 mg finerenone suspension (10 mL) in fasted state (Treatment C) in the third intervention period; followed by a single oral dose of 20 mg finerenone crushed and re-suspended film-coated tablet in fasted state (Treatment B) in the fourth intervention period. A wash-out period of at least 72 hours was maintained between finerenone administrations. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Treatment B-C-D-A
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Subjects who followed treatment sequence B-C-D-A in fasted and fed state were reported. Subjects received a single oral dose of 20 mg finerenone crushed and re-suspended film-coated tablet in fasted state (Treatment B) in the first intervention period; followed by a single oral dose of 20 mg finerenone suspension (10 mL) in fasted state (Treatment C) in the second intervention period; followed by a single oral dose of 20 mg finerenone suspension (10 mL) after a standardized high-fat, high-calorie American breakfast in fed state (Treatment D) in the third intervention period; followed by a single oral dose of 20 mg finerenone intact film-coated tablet in fasted state (Treatment A) in the fourth intervention period. A wash-out period of at least 72 hours was maintained between finerenone administrations. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Treatment C-A-B-D
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Subjects who followed treatment sequence C-A-B-D in fasted and fed state were reported. Subjects received a single oral dose of 20 mg finerenone suspension (10 mL) in fasted state (Treatment C) in the first intervention period; followed by a single oral dose of 20 mg finerenone intact film-coated tablet in fasted state (Treatment A) in the second intervention period; followed by a single oral dose of 20 mg finerenone crushed and re-suspended film-coated tablet in fasted state (Treatment B) in the third intervention period; followed by a single oral dose of 20 mg finerenone suspension (10 mL) after a standardized high-fat, high-calorie American breakfast in fed state (Treatment D) in the fourth intervention period. A wash-out period of at least 72 hours was maintained between finerenone administrations. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Treatment D-B-A-C
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Subjects who followed treatment sequence D-B-A-C in fed and fasted state were reported. Subjects received a single oral dose of 20 mg finerenone suspension (10 mL) after a standardized high-fat, high-calorie American breakfast in fed state (Treatment D) in the first intervention period; followed by a single oral dose of 20 mg finerenone crushed and re-suspended film-coated tablet in fasted state (Treatment B) in the second intervention period; followed by a single oral dose of 20 mg finerenone intact film-coated tablet in fasted state (Treatment A) in the third intervention period; followed by a single oral dose of 20 mg finerenone suspension (10 mL) in fasted state (Treatment C) in the fourth intervention period. A wash-out period of at least 72 hours was maintained between finerenone administrations. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
End points reporting groups
|
|||
Reporting group title |
Treatment A-D-C-B
|
||
Reporting group description |
Subjects who followed treatment sequence A-D-C-B in fasted and fed state were reported. Subjects received a single oral dose of 20 mg finerenone (BAY94-8862) intact film-coated tablet in fasted state (Treatment A) in the first intervention period; followed by a single oral dose of 20 mg finerenone suspension (10 milliliter [mL]) after a standardized high-fat, high-calorie American breakfast in fed state (Treatment D) in the second intervention period; followed by a single oral dose of 20 mg finerenone suspension (10 mL) in fasted state (Treatment C) in the third intervention period; followed by a single oral dose of 20 mg finerenone crushed and re-suspended film-coated tablet in fasted state (Treatment B) in the fourth intervention period. A wash-out period of at least 72 hours was maintained between finerenone administrations. | ||
Reporting group title |
Treatment B-C-D-A
|
||
Reporting group description |
Subjects who followed treatment sequence B-C-D-A in fasted and fed state were reported. Subjects received a single oral dose of 20 mg finerenone crushed and re-suspended film-coated tablet in fasted state (Treatment B) in the first intervention period; followed by a single oral dose of 20 mg finerenone suspension (10 mL) in fasted state (Treatment C) in the second intervention period; followed by a single oral dose of 20 mg finerenone suspension (10 mL) after a standardized high-fat, high-calorie American breakfast in fed state (Treatment D) in the third intervention period; followed by a single oral dose of 20 mg finerenone intact film-coated tablet in fasted state (Treatment A) in the fourth intervention period. A wash-out period of at least 72 hours was maintained between finerenone administrations. | ||
Reporting group title |
Treatment C-A-B-D
|
||
Reporting group description |
Subjects who followed treatment sequence C-A-B-D in fasted and fed state were reported. Subjects received a single oral dose of 20 mg finerenone suspension (10 mL) in fasted state (Treatment C) in the first intervention period; followed by a single oral dose of 20 mg finerenone intact film-coated tablet in fasted state (Treatment A) in the second intervention period; followed by a single oral dose of 20 mg finerenone crushed and re-suspended film-coated tablet in fasted state (Treatment B) in the third intervention period; followed by a single oral dose of 20 mg finerenone suspension (10 mL) after a standardized high-fat, high-calorie American breakfast in fed state (Treatment D) in the fourth intervention period. A wash-out period of at least 72 hours was maintained between finerenone administrations. | ||
Reporting group title |
Treatment D-B-A-C
|
||
Reporting group description |
Subjects who followed treatment sequence D-B-A-C in fed and fasted state were reported. Subjects received a single oral dose of 20 mg finerenone suspension (10 mL) after a standardized high-fat, high-calorie American breakfast in fed state (Treatment D) in the first intervention period; followed by a single oral dose of 20 mg finerenone crushed and re-suspended film-coated tablet in fasted state (Treatment B) in the second intervention period; followed by a single oral dose of 20 mg finerenone intact film-coated tablet in fasted state (Treatment A) in the third intervention period; followed by a single oral dose of 20 mg finerenone suspension (10 mL) in fasted state (Treatment C) in the fourth intervention period. A wash-out period of at least 72 hours was maintained between finerenone administrations. | ||
Subject analysis set title |
Safety analysis set (SAF)
|
||
Subject analysis set type |
Safety analysis | ||
Subject analysis set description |
SAF (N=16) included all subjects who received at least one dose of the study medication.
|
||
Subject analysis set title |
Pharmacokinetic analysis set (PKS)
|
||
Subject analysis set type |
Sub-group analysis | ||
Subject analysis set description |
PKS (N=16) included all subjects with a valid PK profile for at least two of the treatments relevant for comparison (Treatment A and B or Treatment A and C or Treatment C and D).
|
||
Subject analysis set title |
Finerenone 20 mg Intact Tablet Fasted (Treatment A)
|
||
Subject analysis set type |
Sub-group analysis | ||
Subject analysis set description |
Subjects (N=16) received a single oral dose of 20 mg finerenone intact film-coated tablet in fasted state during any intervention period.
|
||
Subject analysis set title |
Finerenone 20 mg Crushed Tablet Fasted (Treatment B)
|
||
Subject analysis set type |
Sub-group analysis | ||
Subject analysis set description |
Subjects (N=16) received a single oral dose of 20 mg finerenone crushed and re-suspended film-coated tablet in fasted state during any intervention period.
|
||
Subject analysis set title |
Finerenone 20 mg Suspension Fasted (Treatment C)
|
||
Subject analysis set type |
Sub-group analysis | ||
Subject analysis set description |
Subjects (N=16) received a single oral dose of 20 mg finerenone suspension (10 mL) in fasted state during any intervention period.
|
||
Subject analysis set title |
Finerenone 20 mg Suspension Fed (Treatment D)
|
||
Subject analysis set type |
Sub-group analysis | ||
Subject analysis set description |
Subjects (N=16) received a single oral dose of 20 mg finerenone suspension (10 mL) after a standardized high-fat, high-calorie American breakfast in fed state during any intervention period.
|
|
|||||||||||||||||||||
End point title |
Maximum Observed Concentration (Cmax) After Single Dose Administration of Finerenone in Plasma | ||||||||||||||||||||
End point description |
Maximum observed concentration of finerenone in plasma after single dose administration was measured. Geometric mean and percentage geometric coefficient of variation (%CV) were reported.
|
||||||||||||||||||||
End point type |
Primary
|
||||||||||||||||||||
End point timeframe |
Pre-dose to 24 hours post-dose
|
||||||||||||||||||||
|
|||||||||||||||||||||
Statistical analysis title |
Statistical analysis: Treatment (C)/Treatment (A) | ||||||||||||||||||||
Statistical analysis description |
Cmax of finerenone were analyzed using analysis of variance (ANOVA) including sequence, subject (sequence), period, and treatment effects. Based on these analysis point estimates (least squares (LS)-means) and exploratory 90 percent (%) confidence intervals (CIs) for the ratios “20 mg suspension fasted (C)/20 mg intact tablet fasted (A)” of Cmax were calculated. Database auto-calculate number of subjects analysed, but the actual number of subjects analysed was 16.
|
||||||||||||||||||||
Comparison groups |
Finerenone 20 mg Intact Tablet Fasted (Treatment A) v Finerenone 20 mg Suspension Fasted (Treatment C)
|
||||||||||||||||||||
Number of subjects included in analysis |
32
|
||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||
Analysis type |
other | ||||||||||||||||||||
Method |
ANOVA | ||||||||||||||||||||
Parameter type |
Estimated ratio in percent [%] | ||||||||||||||||||||
Point estimate |
122.9
|
||||||||||||||||||||
Confidence interval |
|||||||||||||||||||||
level |
90% | ||||||||||||||||||||
sides |
2-sided
|
||||||||||||||||||||
lower limit |
104.48 | ||||||||||||||||||||
upper limit |
144.56 | ||||||||||||||||||||
Statistical analysis title |
Statistical analysis: Treatment (D)/Treatment (C) | ||||||||||||||||||||
Statistical analysis description |
Cmax of finerenone were analyzed using ANOVA including sequence, subject (sequence), period, and treatment effects. Based on these analysis point estimates (LS-means) and exploratory 90% CIs for the ratios “20 mg suspension fed (D)/20 mg suspension fasted (C)” of Cmax were calculated. Database auto-calculate number of subjects analysed, but the actual number of subjects analysed was 16.
|
||||||||||||||||||||
Comparison groups |
Finerenone 20 mg Suspension Fasted (Treatment C) v Finerenone 20 mg Suspension Fed (Treatment D)
|
||||||||||||||||||||
Number of subjects included in analysis |
32
|
||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||
Analysis type |
other | ||||||||||||||||||||
Method |
ANOVA | ||||||||||||||||||||
Parameter type |
Estimated ratio in % | ||||||||||||||||||||
Point estimate |
58.02
|
||||||||||||||||||||
Confidence interval |
|||||||||||||||||||||
level |
90% | ||||||||||||||||||||
sides |
2-sided
|
||||||||||||||||||||
lower limit |
49.32 | ||||||||||||||||||||
upper limit |
68.25 | ||||||||||||||||||||
Statistical analysis title |
Statistical analysis: Treatment (B)/Treatment (A) | ||||||||||||||||||||
Statistical analysis description |
Cmax of finerenone were analyzed using ANOVA including sequence, subject (sequence), period, and treatment effects. Based on these analysis point estimates (LS-means) and exploratory 90% CIs for the ratios “20 mg crushed/re-suspended tablet fasted (B)/20 mg intact tablet fasted (A)” of Cmax were calculated. Database auto-calculate number of subjects analysed, but the actual number of subjects analysed was 16.
|
||||||||||||||||||||
Comparison groups |
Finerenone 20 mg Intact Tablet Fasted (Treatment A) v Finerenone 20 mg Crushed Tablet Fasted (Treatment B)
|
||||||||||||||||||||
Number of subjects included in analysis |
32
|
||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||
Analysis type |
other | ||||||||||||||||||||
Method |
ANOVA | ||||||||||||||||||||
Parameter type |
Estimated ratio in % | ||||||||||||||||||||
Point estimate |
89.04
|
||||||||||||||||||||
Confidence interval |
|||||||||||||||||||||
level |
90% | ||||||||||||||||||||
sides |
2-sided
|
||||||||||||||||||||
lower limit |
75.69 | ||||||||||||||||||||
upper limit |
104.74 |
|
|||||||||||||||||||||
End point title |
Area Under Concentration Versus Time Curve From Zero to Infinity (AUC) After Single Dose Administration of Finerenone in Plasma | ||||||||||||||||||||
End point description |
Area under the concentration versus time curve from zero to infinity after single dose administration of finerenone in plasma was measured. Geometric mean and percentage geometric coefficient of variation (%CV) were reported.
|
||||||||||||||||||||
End point type |
Primary
|
||||||||||||||||||||
End point timeframe |
Pre-dose to 24 hours post-dose
|
||||||||||||||||||||
|
|||||||||||||||||||||
Notes [1] - PKS [2] - PKS [3] - PKS [4] - PKS |
|||||||||||||||||||||
Statistical analysis title |
Statistical analysis: Treatment (C)/Treatment (A) | ||||||||||||||||||||
Statistical analysis description |
AUC of finerenone were analyzed using ANOVA including sequence, subject (sequence), period, and treatment effects. Based on these analysis point estimates (LS-means) and exploratory 90% CIs for the ratios “20 mg suspension fasted (C)/20 mg intact tablet fasted (A)” of AUC were calculated. Database auto calculate number of subjects analyzed, but the actual number of subjects analyzed was 16.
|
||||||||||||||||||||
Comparison groups |
Finerenone 20 mg Intact Tablet Fasted (Treatment A) v Finerenone 20 mg Suspension Fasted (Treatment C)
|
||||||||||||||||||||
Number of subjects included in analysis |
32
|
||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||
Analysis type |
other | ||||||||||||||||||||
Method |
ANOVA | ||||||||||||||||||||
Parameter type |
Estimated ratio in % | ||||||||||||||||||||
Point estimate |
104.55
|
||||||||||||||||||||
Confidence interval |
|||||||||||||||||||||
level |
90% | ||||||||||||||||||||
sides |
2-sided
|
||||||||||||||||||||
lower limit |
95.85 | ||||||||||||||||||||
upper limit |
114.04 | ||||||||||||||||||||
Statistical analysis title |
Statistical analysis: Treatment (B)/Treatment (A) | ||||||||||||||||||||
Statistical analysis description |
AUC of finerenone were analyzed using ANOVA including sequence, subject (sequence), period, and treatment effects. Based on these analysis point estimates (LS-means) and exploratory 90% CIs for the ratios “20 mg crushed/re-suspended tablet fasted (B)/20 mg intact tablet fasted (A)” of AUC were calculated. Database auto calculate number of subjects analyzed, but the actual number of subjects analyzed was 16.
|
||||||||||||||||||||
Comparison groups |
Finerenone 20 mg Intact Tablet Fasted (Treatment A) v Finerenone 20 mg Crushed Tablet Fasted (Treatment B)
|
||||||||||||||||||||
Number of subjects included in analysis |
32
|
||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||
Analysis type |
other | ||||||||||||||||||||
Method |
ANOVA | ||||||||||||||||||||
Parameter type |
Estimated ratio in % | ||||||||||||||||||||
Point estimate |
81.61
|
||||||||||||||||||||
Confidence interval |
|||||||||||||||||||||
level |
90% | ||||||||||||||||||||
sides |
2-sided
|
||||||||||||||||||||
lower limit |
74.82 | ||||||||||||||||||||
upper limit |
89.02 | ||||||||||||||||||||
Statistical analysis title |
Statistical analysis: Treatment (D)/Treatment (C) | ||||||||||||||||||||
Statistical analysis description |
AUC of finerenone were analyzed using ANOVA including sequence, subject (sequence), period, and treatment effects. Based on these analysis point estimates (LS-means) and exploratory 90% CIs for the ratios “20 mg suspension fed (D)/20 mg suspension fasted (C)” of AUC were calculated. Database auto calculate number of subjects analyzed, but the actual number of subjects analyzed was 16.
|
||||||||||||||||||||
Comparison groups |
Finerenone 20 mg Suspension Fasted (Treatment C) v Finerenone 20 mg Suspension Fed (Treatment D)
|
||||||||||||||||||||
Number of subjects included in analysis |
32
|
||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||
Analysis type |
other | ||||||||||||||||||||
Method |
ANOVA | ||||||||||||||||||||
Parameter type |
Estimated ratio in % | ||||||||||||||||||||
Point estimate |
100.37
|
||||||||||||||||||||
Confidence interval |
|||||||||||||||||||||
level |
90% | ||||||||||||||||||||
sides |
2-sided
|
||||||||||||||||||||
lower limit |
92.02 | ||||||||||||||||||||
upper limit |
109.48 |
|
||||||||||||||||||||||||||
End point title |
Number of Subjects With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs) | |||||||||||||||||||||||||
End point description |
An adverse event (AE) was any untoward medical occurrence in subject who received study drug without regard to possibility of causal relationship. A serious adverse event (SAE) was an AE resulting in any of following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly/birth defect and another serious or important medical event as judged by the investigator. AE/SAEs that started or worsened after study drug treatment were recorded as TEAE/TESAEs.
|
|||||||||||||||||||||||||
End point type |
Secondary
|
|||||||||||||||||||||||||
End point timeframe |
From start of study drug administration up to 1 week after last drug administration (Day 16)
|
|||||||||||||||||||||||||
|
||||||||||||||||||||||||||
Notes [5] - SAF [6] - SAF [7] - SAF [8] - SAF |
||||||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||
End point title |
Appearance of the Formulation Assessed by Questionnaire | ||||||||||||||||||||||||
End point description |
Subjects completed a questionnaire regarding appearance immediately after study drug administration. Subjects were asked the question as ‘I like the appearance of the medium’, where subjects were selected their response from one of the five items: ‘completely disagree’, ‘somewhat disagree’, ‘neutral’, ‘somewhat agree’ and ‘completely agree’. In the below table, the response for categories ‘completely disagree’, ‘somewhat disagree’ were summarized under "disliked" and response from categories ‘somewhat agree’ and ‘completely agree’ were summarized under "liked".
|
||||||||||||||||||||||||
End point type |
Other pre-specified
|
||||||||||||||||||||||||
End point timeframe |
Immediately after study drug administration
|
||||||||||||||||||||||||
|
|||||||||||||||||||||||||
Notes [9] - SAF [10] - SAF [11] - SAF |
|||||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||
End point title |
Taste of the Formulation Assessed by Questionnaire | ||||||||||||||||||||||||
End point description |
Subjects completed a questionnaire regarding taste immediately after study drug administration. Subjects were asked the question as ‘I like the taste after swallowing’, where subjects were selected their response from one of the five items: ‘completely disagree’, ‘somewhat disagree’, ‘neutral’, ‘somewhat agree’ and ‘completely agree’. In the below table, the response for categories ‘completely disagree’, ‘somewhat disagree’ were summarized under "disliked" and response from categories ‘somewhat agree’ and ‘completely agree’ were summarized under "liked".
|
||||||||||||||||||||||||
End point type |
Other pre-specified
|
||||||||||||||||||||||||
End point timeframe |
Immediately after study drug administration
|
||||||||||||||||||||||||
|
|||||||||||||||||||||||||
Notes [12] - SAF [13] - SAF [14] - SAF |
|||||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||
End point title |
Smell of the Formulation Assessed by Questionnaire | ||||||||||||||||||||||||
End point description |
Subjects completed a questionnaire regarding smell immediately after study drug administration. Subjects were asked the question as ‘I like the smell of the medium’, where subjects were selected their response from one of the five items: ‘completely disagree’, ‘somewhat disagree’, ‘neutral’, ‘somewhat agree’ and ‘completely agree’. In the below table, the response for categories ‘completely disagree’, ‘somewhat disagree’ were summarized under "disliked" and response from categories ‘somewhat agree’ and ‘completely agree’ were summarized under "liked".
|
||||||||||||||||||||||||
End point type |
Other pre-specified
|
||||||||||||||||||||||||
End point timeframe |
Immediately after study drug administration
|
||||||||||||||||||||||||
|
|||||||||||||||||||||||||
Notes [15] - SAF [16] - SAF [17] - SAF |
|||||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||
End point title |
Overall Impression of the Formulation Assessed by Questionnaire | ||||||||||||||||||||||||
End point description |
Subjects completed a questionnaire regarding overall impression immediately after study drug administration. Subjects were asked the question as ‘I like the medium overall’, where subjects were selected their response from one of the five items: ‘completely disagree’, ‘somewhat disagree’, ‘neutral’, ‘somewhat agree’ and ‘completely agree’. In the below table, the response for categories ‘completely disagree’, ‘somewhat disagree’ were summarized under "disliked" and response from categories ‘somewhat agree’ and ‘completely agree’ were summarized under "liked".
|
||||||||||||||||||||||||
End point type |
Other pre-specified
|
||||||||||||||||||||||||
End point timeframe |
Immediately after study drug administration
|
||||||||||||||||||||||||
|
|||||||||||||||||||||||||
Notes [18] - SAF [19] - SAF [20] - SAF |
|||||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
End point title |
Texture of the Formulation Assessed by Questionnaire | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
End point description |
Subjects completed a questionnaire regarding texture immediately after study drug administration. Subjects were asked the question as ‘texture like sand, sticky, dry, creamy and strange (unlike any of the above mentioned) or other feeling’, where subjects were selected their response from one of the five items: ‘completely disagree’, ‘somewhat disagree’, ‘neutral’, ‘somewhat agree’ and ‘completely agree’. In the below table, the response for categories ‘completely disagree’, ‘somewhat disagree’ were summarized under "disliked" and response from categories ‘somewhat agree’ and ‘completely agree’ were summarized under "liked".
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
End point type |
Other pre-specified
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
End point timeframe |
Immediately after study drug administration
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Notes [21] - SAF [22] - SAF [23] - SAF |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||
End point title |
Whether Oro-dispersible Tablets are Palatable and Swallowable Assessed by Questionnaire | ||||||||||||||||||||||||
End point description |
Subjects completed a questionnaire regarding palatable and swallowable immediately after study drug administration. Subjects were asked the question as ‘It was easy for me to swallow’, where subjects were selected their response from one of the two items: ‘somewhat disagree’, and ‘completely agree’. In the below table, the response for category ‘somewhat disagree’ was summarized under "disliked" and response from category ‘completely agree’ was summarized under "liked".
|
||||||||||||||||||||||||
End point type |
Other pre-specified
|
||||||||||||||||||||||||
End point timeframe |
Immediately after study drug administration
|
||||||||||||||||||||||||
|
|||||||||||||||||||||||||
Notes [24] - SAF [25] - SAF [26] - SAF |
|||||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Adverse events information
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Timeframe for reporting adverse events |
From the start of study drug administration up to 1 week after the last drug administration (Day 16)
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Assessment type |
Non-systematic | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary used for adverse event reporting
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary name |
MedDRA | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary version |
19.1
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Finerenone, 20mg Intact Tablet Fasted
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Subjects received a single oral dose of 20 mg finerenone intact film-coated tablet in fasted state during any intervention period. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Finerenone, 20mg Crushed Tablet Fasted
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Subjects received a single oral dose of 20 mg finerenone crushed and re-suspended film-coated tablet in fasted state during any intervention period. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Finerenone, 20mg Suspension Fasted
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Subjects received a single oral dose of 20 mg finerenone suspension (10 mL) in fasted state during any intervention period. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Finerenone, 20mg Suspension Fed
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Subjects received a single oral dose of 20 mg finerenone suspension (10 mL) after a standardized high-fat, high-calorie American breakfast in fed state during any intervention period. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Frequency threshold for reporting non-serious adverse events: 0% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
Substantial protocol amendments (globally) |
|||
Were there any global substantial amendments to the protocol? No | |||
Interruptions (globally) |
|||
Were there any global interruptions to the trial? No | |||
Limitations and caveats |
|||
Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data. | |||
Occurrence of "±” in relation with geometric CV is auto-generated and cannot be deleted. Decimal places were automatically truncated if last decimal equals zero. |